在慢性心力衰竭中,β-上腺素激动剂和抗剂对功能能力和存活率的影响的病理生理机制
1Department of Medicine, Mount Sinai School of Medicine, City University of New York, NY 10029.
Circulation
|August 1, 1990
概括
针对交感神经系统的药物可以改变慢性心力衰竭. 贝塔受体激动剂和对抗剂提供了好处,但也带来了风险,强调了特定受体作用的重要性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 身体生理学 身体生理学
背景情况:
- 慢性心力衰竭 (CHF) 影响交感神经系统 (SNS) 活动.
- 调节SNS效应在CHF患者中具有治疗潜力.
研究的目的:
- 审查调节慢性心力衰竭中SNS的药物的作用.
- 探索β-上腺素受体亚型 (β1和β2) 在CHF治疗中的不同作用.
主要方法:
- 对CHF中SNS调节药物的受控临床试验的分析.
- 对心脏功能,心律失常和死亡率的药理学影响的审查.
- 检查β1-对比β2-上腺素受体的作用.
主要成果:
- 贝塔受体激动剂可以改善腹结功能,但可能导致心律失常.
- β受体对抗剂可能会改善缩性表现并降低死亡率,但可能会恶化心力衰竭.
- 益处通常由β1受体介导,而不良影响则与β2受体相互作用有关.
结论:
- 选择性向β1受体是新型冠状动脉炎治疗的合理方法.
- 了解受体特异性影响对于优化心力衰竭中SNS调节治疗至关重要.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...


